We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

10 hedge funds and large institutions have $2.92M invested in Cellectar Biosciences in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.24% less ownership

Funds ownership: 16.03% → 13.79% (-2.2%)

17% less funds holding

Funds holding: 12 → 10 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

77% less capital inflows, than outflows

Capital inflows: $131K | Capital outflows: $558K

Holders
10
Holders Change
-2
Holders Change %
-16.67%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$38K
2
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
+$17.2K

Top Sellers

Rank Fund Capital Flow
1
Tang Capital Management
Tang Capital Management
California
-$471K
2
Morgan Stanley
Morgan Stanley
New York
-$34.3K
3
JP Morgan Chase
JP Morgan Chase
New York
-$21K
4
Private Advisor Group
Private Advisor Group
New Jersey
-$20K
5
Ladenburg Thalmann Financial Services
Ladenburg Thalmann Financial Services
Florida
-$8.84K

CLRB Hedge Fund Activity: Q4 2019 in Review

10 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q4 2019, worth a combined $2.92M — down 3% from $3.01M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CLRB and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was Renaissance Technologies, adding an estimated $38K. The largest seller was Tang Capital Management, exiting entirely with an estimated $471K sold.

  • 10 institutional investors held Cellectar Biosciences (CLRB) as of Q4 2019, down from 12 in Q3 2019.
  • Funds reported $2.92M of Cellectar Biosciences stock for Q4 2019, down 3% quarter-over-quarter.
  • 2 funds opened new Cellectar Biosciences positions in Q4 2019 and 4 closed out, a net change of -2 holders.
  • The largest Cellectar Biosciences buyer in Q4 2019 was Renaissance Technologies, an estimated $38K added.
  • The largest Cellectar Biosciences seller in Q4 2019 was Tang Capital Management, an estimated $471K sold.

Based on aggregated 13F filings for Q4 2019.